VIP is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
VIP is being researched for inflammation applications. Activates VPAC1 and VPAC2 class B G protein-coupled receptors, initiating adenylyl cyclase-cAMP cascade and CREB phosphorylation. Drives smooth muscle relaxation via calcium channel modulation, vasodi. Common dosages for this use range from 50-100 mcg per spray or 200 mcg daily inhaled 4 times daily (nasal) or daily (inhaled).
Can VIP Help With Inflammation?
VIP (Vasoactive Intestinal Peptide) is being researched for inflammation applications based on its mechanism as a Neuropeptide, vasodilator, anti-inflammatory.
Activates VPAC1 and VPAC2 class B G protein-coupled receptors, initiating adenylyl cyclase-cAMP cascade and CREB phosphorylation. Drives smooth muscle relaxation via calcium channel modulation, vasodilation through nitric oxide and prostacyclin production, neuroprotection via anti-inflammatory IL-10 induction, and enhanced insulin secretion via VPAC2 signaling.
What Does the Research Show for VIP and Inflammation?
Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
The relevance to inflammation specifically comes from VIP's effects on vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
What Protocol Is Used for Inflammation?
For inflammation applications, the standard VIP protocol is 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) via intranasal spray or inhalation for ongoing continuous therapy.
Some researchers adjust dosing based on the specific inflammation application — see our VIP dosage guide for full protocol details.
Can Stacking Improve Inflammation Results?
Combines with inhaled corticosteroids or bronchodilators for synergistic airway relaxation in asthma/COPD.
What Side Effects Apply to Inflammation Use?
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies.
Side effects are generally consistent regardless of the specific application. See our VIP side effects guide for details.
Calculate Your VIP Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for VIP.
Open Calculator →Bottom Line: VIP for Inflammation
VIP shows preliminary research potential for inflammation. Standard protocols (50-100 mcg per spray or 200 mcg daily inhaled, 4 times daily (nasal) or daily (inhaled), ongoing continuous therapy) apply.
Source from COA-tested vendors and maintain consistent dosing for the full cycle duration.
Complete Guide
VIP : Benefits, Dosage, Side Effects & Research
Related Reading
Research-Grade Sourcing
If you're going to research VIP, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is VIP?
VIP (Vasoactive Intestinal Peptide) is a Neuropeptide, vasodilator, anti-inflammatory. Endogenous 28-amino acid neuropeptide produced in gut, pancreas, brain, and neuroendocrine tissues. It is researched for vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
What is the recommended VIP dosage?
Common dosages: 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) via intranasal spray or inhalation. Cycle length: ongoing continuous therapy. Half-life: 2 minutes (extremely short). Use our peptide calculator for exact reconstitution math.
What are the side effects of VIP?
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies.
Is VIP safe?
VIP has shown a favorable safety profile in research. Not FDA-approved. Orphan drug designation for pulmonary hypertension. FDA announced plans to remove from compounding lists. All research should follow appropriate safety protocols.